Zepbound (tirzepatide) and similar GLP-1 drugs have transformed weight loss treatment, with clinical trials showing 20% body weight reduction in many patients
The oncogenic potential of growth hormone
Cagrilintide amylin pathway Cagrilintide is a long-acting amylin analogue described in the literature as a dual amylin and calcitonin receptor agonist (DACRA)
Semaglutides superior effectiveness in weight loss is backed by numerous clinical studies, demonstrating that patients can lose an average of 15-20% of their body weight over the course of a year, far exceeding the results typically seen with Saxenda
Ozempics primary approval is for the management of type 2 diabetes, as it helps regulate blood sugar levels by mimicking the GLP-1 hormone, which also can promote weight loss as a secondary effect
: Planned adoption includes () on residual solvents, () specification revisions and for oligonucleotide therapeutics